Focused On-demand Library for Lysophospholipase D GDPD3

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.







Alternative names:

Glycerophosphodiester phosphodiesterase 7; Glycerophosphodiester phosphodiesterase domain-containing protein 3

Alternative UPACC:

Q7L5L3; Q9H652


Lysophospholipase D GDPD3, also known as Glycerophosphodiester phosphodiesterase 7 and Glycerophosphodiester phosphodiesterase domain-containing protein 3, plays a crucial role in lipid metabolism. It hydrolyzes lysoglycerophospholipids to produce lysophosphatidic acid (LPA) and corresponding amines, showing a preference for specific substrates such as 1-O-alkyl-sn-glycero-3-phosphocholine and lysophosphatidylcholine. This enzymatic activity is pivotal in the regulation of various biological processes.

Therapeutic significance:

Understanding the role of Lysophospholipase D GDPD3 could open doors to potential therapeutic strategies. Its involvement in lipid metabolism and production of bioactive lipids like LPA suggests its potential impact on diseases related to lipid dysregulation.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.